title: The need for cost-effective choices to treat patients with bipolar 1 disorders including asenapine.
abstract: BACKGROUND
  Bipolar 1 disorders (BPD) are a chronic disorder with prevalence rates of up to 2.6% of the adult population or higher and appreciable direct and indirect costs. As a result, these are a concern to health authorities especially given the low age of onset. Consequently, there is a need to treat BPD patients well and improve their quality-of-life. Pharmacotherapy includes mood stabilizers and atypical antipsychotics (AAPs). AAPs have different mechanisms of action and side-effects, so treatment needs to be tailored. Asenapine in clinical trials is as effective as olanzapine, with less metabolic side-effects.
  
  
  METHODS
  Chitnis and colleagues assessed the cost-effectiveness of asenapine among patients in healthcare databases.
  
  
  CONCLUSIONS
  They showed in routine care that asenapine also reduces hospital and emergency room admissions, making it cost neutral in BPD, which is of interest to health authorities and clinicians.
authors: a a Department of Laboratory Medicine, Division of Clinical Pharmacology , Karolinska Institutet, Karolinska University Hospital Huddinge , Stockholm , Sweden.|b b Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde , Glasgow , UK.
authors: Brian
authors: B
authors: Godman
mesh_terms: D001714:Bipolar Disorder / Q000188:drug therapy* / Q000191:economics*; D005260:Female; D006296:Health Services / Q000191:economics* / Q000706:statistics & numerical data*; D006576:Heterocyclic Compounds, 4 or More Rings / Q000627:therapeutic use*; D006801:Humans; D008297:Male
chemical_list: D006576:Heterocyclic Compounds, 4 or More Rings
keywords: Asenapine; Atypical antipsychotics; Bipolar 1 disorder; Quality-of-life